Pharmaceuticals

Global Fabry Disease Market 2025–2029: Competitive Insights and Opportunities

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Fabry Disease Industry In 2025?

The fabry disease market size has experienced strong growth in recent years. It is forecast to expand from $2.1 billion in 2024 to $2.26 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%. The historical increase can be attributed to several factors such as greater awareness and diagnosis of rare diseases, the development of specialized healthcare infrastructure, government incentives and orphan drug designations, an increase in funding for rare disease research, and the initial market introduction of therapies.

The market size for Fabry disease is projected to experience robust growth in the coming years. It is anticipated to expand to $3.04 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.7%. This expansion during the forecast period is primarily driven by the proliferation of newborn screening programs, increased regulatory support for orphan and rare disease medications, enhanced access to healthcare, the rise of telemedicine and remote care services, and the escalating demand for personalized medicine. Noteworthy trends anticipated in this period include the wider adoption of enzyme replacement therapy, continuous progress in genetic testing, the integration of AI and digital tools for earlier detection, the development of AI-powered diagnostic algorithms, and breakthroughs in gene therapy.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24218&type=smp

What Are The Key Drivers Of Growth In The Fabry Disease Market?

The fabry disease market is anticipated to expand due to an increasing emphasis on personalized medicine. This treatment approach involves customizing medical care and therapies for individuals by utilizing information about their genes, environment, and lifestyle to achieve better outcomes. The rising focus on personalized medicine is fueled by its capacity to improve treatment effectiveness and reduce side effects through tailoring therapies to individual patient needs. It helps formulate treatment plans based on a patient’s specific genetic mutation and disease severity, thereby enhancing outcomes and minimizing unnecessary side effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, highlighted that in 2023, the FDA granted approval for 16 new personalized treatments for rare disease patients, which was a substantial increase from the six approvals in 2022. Thus, the growing attention on personalized medicine is propelling the growth of the fabry disease market.

What Are The Different Segment Classifications Within The Fabry Disease Market?

The fabry disease market covered in this report is segmented –

1) By Type: Type 1, Type 2, Other Types

2) By Treatment: Enzyme Replacement Therapy, Oral Therapy, Adjunct Therapy, Other Treatments

3) By Diagnosis: Blood Test, Genetic Test, Parenteral Test, Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Type 1: Classic Fabry Disease, Later-Onset Fabry Disease

2) By Type 2: Cardiovascular-Focused Fabry Disease, Renal-Focused Fabry Disease

3) By Other Types: Variant Fabry Disease, X-linked Fabry Disease

What Key Innovation Trends Are Fueling Advancements In The Fabry Disease Market?

Leading firms in the fabry disease market are concentrating on creating novel treatments, including PEGylated enzyme replacement therapy (ERT), with the aim of boosting treatment effectiveness, increasing patient adherence, and lowering immune reactions commonly linked to standard ERTs. PEGylated enzyme replacement therapy (ERT) represents an altered version of conventional ERT, where polyethylene glycol (PEG) chains are linked to the enzyme to improve its stability, extend its presence in the body’s circulation, and diminish immune system responses. As an illustration, in May 2023, Chiesi Global Rare Diseases, which is a part of the Chiesi Group, an Italy-based pharmaceutical company, revealed that the U.S. Food and Drug Administration (FDA), a US-based government agency, had granted approval for PRX-102 (pegunigalsidase alfa) to treat adult Fabry disease patients. This approval stems from a comprehensive clinical program involving more than 140 patients and a follow-up period extending up to 7.5 years, showcasing the therapy’s effectiveness in decreasing renal Gb3 deposits and sustaining kidney function, alongside a positive safety record.

Which Major Industry Participants Are Leading The Fabry Disease Market Growth?

Major companies operating in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/fabry-disease-global-market-report

Which Region Is Projected To Lead The Fabry Disease Market During The Forecast Period?

North America was the largest region in the fabry disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Fabry Disease Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24218&type=smp

Browse Through More Reports Similar to the Global Fabry Disease Market 2025, By The Business Research Company

Genetic Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

Epigenetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/epigenetics-global-market-report

Genetic Testing Market 2025

https://www.thebusinessresearchcompany.com/report/genetic-testing-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795